Rigel Pharmaceuticals, Inc. (RIGL) Revenue History
Annual and quarterly revenue from 1999 to present
RIGL Revenue Over Time (1999–2025)
RIGL Revenue Growth History
15 of 25 years with positive growth- FY1999 revenue growth
- N/A
- FY2000 revenue growth
- +47.1%
- FY2001 revenue growth
- +15.8%
- FY2002 revenue growth
- +3.2%
- FY2003 revenue growth
- -30.0%
- FY2004 revenue growth
- -57.2%
- FY2005 revenue growth
- +249.2%
- FY2006 revenue growth
- +102.5%
- FY2007 revenue growth
- -62.4%
- FY2008 revenue growth
- -100.0%
- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- +16566.7%
- FY2011 revenue growth
- -96.2%
- FY2012 revenue growth
- -52.6%
- FY2013 revenue growth
- +217.8%
- FY2014 revenue growth
- +15.4%
- FY2015 revenue growth
- +250.2%
- FY2016 revenue growth
- -29.5%
- FY2017 revenue growth
- -78.0%
- FY2018 revenue growth
- +892.6%
- FY2019 revenue growth
- +33.2%
- FY2020 revenue growth
- +83.2%
- FY2021 revenue growth
- +37.4%
- FY2022 revenue growth
- -19.4%
- FY2023 revenue growth
- -2.8%
- FY2024 revenue growth
- +53.4%
- FY2025 revenue growth
- +64.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $78.7M | -22.6% |
| Q1 2026 | $58.8M | +10.3% |
| Q4 2025 | $69.8M | +21.2% |
| Q3 2025 | $69.5M | +25.6% |
| Q2 2025 | $101.7M | +176.0% |
| Q1 2025 | $53.3M | +80.6% |
| Q4 2024 | $57.6M | +60.9% |
| Q3 2024 | $55.3M | +96.6% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
RIGL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RIGL Revenue Analysis (1999–2025)
Current Revenue & Growth
As of September 22, 2026, Rigel Pharmaceuticals, Inc. (RIGL) generated trailing twelve-month (TTM) revenue of $276.8 million, reflecting significant decline in growth of -22.6% year-over-year. The most recent quarter (Q2 2026) recorded $78.7 million in revenue, up 33.8% sequentially.
Historical Growth Trajectory
RIGL's 5-year compound annual growth rate (CAGR) stands at +22.1%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +34.8% exceeds the 5-year average, indicating an acceleration in the most recent period. Rigel Pharmaceuticals, Inc.'s highest annual revenue of $294.3 million was recorded in 2025, an all-time high.
Revenue by Segment
RIGL's revenue is primarily driven by Product (107%), Contract revenues from collaborations (29%), and Government Contract (0%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including PRTA (+427.3% YoY), FOLD (+20.0% YoY), and RARE (+17.5% YoY) — RIGL has underperformed the peer group in revenue growth. Compare RIGL vs PRTA →
RIGL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RIGLCurrent | $277M | -22.6% | +22.1% | 42.6% | |
 PRTA | $10M | +427.3% | +62.6% | -1905.8% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +17.5% | +19.9% | -79.5% | |
 HALO | $1.4B | +41.2% | +39.2% | 58.4% | |
 PTCT | $1.7B | -42.8% | +35.4% | 49.5% |
RIGL Historical Revenue Data (1999–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $294.3M | +64.1% | $274.7M | 93.3% | $125.5M | 42.6% |
| 2024 | $179.3M | +53.4% | $160.6M | 89.6% | $24.2M | 13.5% |
| 2023 | $116.9M | -2.8% | $109.8M | 93.9% | $-20,491,000 | -17.5% |
| 2022 | $120.2M | -19.4% | $118.5M | 98.5% | $-55,550,000 | -46.2% |
| 2021 | $149.2M | +37.4% | $148.2M | 99.3% | $-12,496,000 | -8.4% |
| 2020 | $108.6M | +83.2% | $107.7M | 99.2% | $-28,973,000 | -26.7% |
| 2019 | $59.3M | +33.2% | $58.4M | 98.5% | $-69,091,000 | -116.5% |
| 2018 | $44.5M | +892.6% | $44.2M | 99.4% | $-72,683,000 | -163.3% |
| 2017 | $4.5M | -78.0% | $-41,785,000 | -931.9% | $-79,616,000 | -1775.6% |
| 2016 | $20.4M | -29.5% | $-43,063,000 | -211.3% | $-69,741,000 | -342.2% |
| 2015 | $28.9M | +250.2% | $-33,930,000 | -117.4% | $-51,743,000 | -179.1% |
| 2014 | $8.3M | +15.4% | $-59,446,000 | -720.6% | $-91,249,000 | -1106.0% |
| 2013 | $7.2M | +217.8% | $-68,178,000 | -953.5% | $-89,469,000 | -1251.3% |
| 2012 | $2.3M | -52.6% | $-76,528,000 | -3401.2% | $-99,377,000 | -4416.8% |
| 2011 | $4.8M | -96.2% | $4.8M | 100.0% | $-86,368,000 | -1818.3% |
RIGL Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
Is RIGL's revenue growth accelerating or slowing?
RIGL revenue is declining -22.6% year-over-year. TTM revenue fell to $277M, contrasting with the 5-year CAGR of +22.1%. The reversal reflects either macro headwinds or company-specific challenges.
What is RIGL's revenue history from 1999 to 2026?
Rigel Pharmaceuticals, Inc. (RIGL) revenue history spans 1999 to 2026. TTM revenue as of 2026 is $277M, growing at -22.6% YoY. The 5-year CAGR is +22.1%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is RIGL's long-term revenue growth rate (CAGR)?
Rigel Pharmaceuticals, Inc.'s 5-year revenue CAGR of +22.1% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -22.6% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for RIGL.
Why does RIGL's quarterly revenue fluctuate?
RIGL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Rigel Pharmaceuticals, Inc.'s revenue data from 1999 to 2026 shows full historical quarterly detail on this page.
How is RIGL's revenue distributed by segment?
RIGL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does RIGL's revenue compare to industry peers?
Rigel Pharmaceuticals, Inc. (RIGL) with TTM revenue of $277M and -22.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.